Multiple clinical trials (NCT04083495, NCT04526834, NCT02917083, NCT01316146, NCT03049449, and NCT02690545) are actively exploring CD30 CAR-T-cell therapy in patients with rare R/R CD30-positive PTCL and classical HL, and are expected to drive new advances in the field. This evidence concerns the gene TNFRSF8 and Hodgkins lymphoma.